Russia’s Nanolek expands cooperation with key foreign partners

▤ Summary

Nanolek is expanding its international cooperation with key foreign partners through a new commercialization agreement. The company will launch armocibart, a hemophilia drug developed by Suzhou Alphamab, in Russia and several Eurasian markets. The agreement covers Russia, other Eurasian Economic Union countries, Uzbekistan, and Azerbaijan. This deal points to broader cross-border licensing and distribution activity in the pharmaceutical sector.

▦ Linked Companies